Posted by Michael Wonder on 24 Sep 2023
US FDA approves Jardiance for the treatment of adults with chronic kidney disease
22 September 2023 - Jardiance (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease, as established in the EMPA-KIDNEY Phase III trial.
The US FDA has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death and hospitalisation in adults with chronic kidney disease at risk of progression, Boehringer Ingelheim and Eli Lilly announced.
